Abarelix  

Abarelix
Systematic (IUPAC) name
acetyl-D--naphthylalanyl- D-4-chlorophenylalanyl-D-3-pyridylalanyl-L-seryl-L- N-methyl- tyrosyl-D-asparagyl-L-leucyl-L-N(e )-isopropyl-lysyl-L-prolyl-D-alanyl-amide
Identifiers
CAS number	183552-38-7
ATC code	L02BX01
PubChem	16131215
DrugBank	BTD00051
ChemSpider	10482301
Chemical data
Formula	C72H95ClN14O14
Mol. mass	1416.06 g/mol
SMILES	eMolecules & PubChem
Pharmacokinetic data
Bioavailability	?
Protein binding	9699%
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?
Y(what is this?)  (verify)

Abarelix is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist). It is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available. It belongs to the family of drugs called Gonadotropin-releasing hormone antagonists.

It is marketed by Speciality European Pharma as Plenaxis. Plenaxis has received marketing authorisation in Germany.

More information can be found at Plenaxis.de [1] and FastProstateControl.com [2].

This pharmacology-related article is a stub. You can help Wikipedia by expanding it. v  d  e